Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sage Says Brexanolone's SRSE Result Doesn't Mean PPD Studies Will Fail

Executive Summary

The Phase III study for brexanolone in super-refractory status epilepticus did not meet its primary endpoint, but Sage is optimistic about the drug's prospects in postpartum depression and its earlier-stage SAGE-217.


Related Content

All Smiles At Sage As Phase III Postpartum Depression Data Are Positive
Biomedtracker’s Best Of J.P. Morgan: 15 Companies To Watch
Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts